Division of Amgen Inc.
Latest From Tularik Inc.
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators
Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
David V Goeddel, PhD, CEO
Jack Anthony, SVP, Bus. & Comm. Dev.
Mary Jean Stempien, MD, VP, Clinical Dev.
- Contact Info
Phone: (650) 825-7000
2 Corporate Dr.
S. San Francisco, CA 94080